Publication:
Metabolic Biomarkers and Neurodegeneration: A Pathway Enrichment Analysis of Alzheimer's Disease, Parkinson's Disease, and Amyotrophic Lateral Sclerosis

Simple item page
dc.contributor.authorKAZAN, DİLEK
dc.contributor.authorsKori, Medi; Aydin, Busra; Unal, Semra; Arga, Kazim Yalcin; Kazan, Dilek
dc.date.accessioned2022-03-12T20:27:11Z
dc.date.available2022-03-12T20:27:11Z
dc.date.issued2016
dc.description.abstractNeurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS) lack robust diagnostics and prognostic biomarkers. Metabolomics is a postgenomics field that offers fresh insights for biomarkers of common complex as well as rare diseases. Using data on metabolite-disease associations published in the previous decade (2006-2016) in PubMed, ScienceDirect, Scopus, and Web of Science, we identified 101 metabolites as putative biomarkers for these three neurodegenerative diseases. Notably, uric acid, choline, creatine, L-glutamine, alanine, creatinine, and N-acetyl-L-aspartate were the shared metabolite signatures among the three diseases. The disease-metabolite-pathway associations pointed out the importance of membrane transport (through ATP binding cassette transporters), particularly of arginine and proline amino acids in all three neurodegenerative diseases. When disease-specific and common metabolic pathways were queried by using the pathway enrichment analyses, we found that alanine, aspartate, glutamate, and purine metabolism might act as alternative pathways to overcome inadequate glucose supply and energy crisis in neurodegeneration. These observations underscore the importance of metabolite-based biomarker research in deciphering the elusive pathophysiology of neurodegenerative diseases. Future research investments in metabolomics of complex diseases might provide new insights on AD, PD, and ALS that continue to place a significant burden on global health.
dc.identifier.doi10.1089/omi.2016.0106
dc.identifier.eissn1557-8100
dc.identifier.issn1536-2310
dc.identifier.pubmed27828769
dc.identifier.urihttps://hdl.handle.net/11424/233638
dc.identifier.wosWOS:000388110600004
dc.language.isoeng
dc.publisherMARY ANN LIEBERT, INC
dc.relation.ispartofOMICS-A JOURNAL OF INTEGRATIVE BIOLOGY
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectmetabolomics
dc.subjectsystems biology
dc.subjectbioinformatics
dc.subjectneurodegeneration
dc.subjectbiomarkers
dc.subjectMILD COGNITIVE IMPAIRMENT
dc.subjectCAUSAL NETWORK ANALYSIS
dc.subjectCEREBROSPINAL-FLUID
dc.subjectAMYLOID-BETA
dc.subjectMASS-SPECTROMETRY
dc.subjectPLASMA
dc.subjectIDENTIFICATION
dc.subjectGLUTAMATE
dc.subjectSERUM
dc.subjectNEUROPROTECTION
dc.titleMetabolic Biomarkers and Neurodegeneration: A Pathway Enrichment Analysis of Alzheimer's Disease, Parkinson's Disease, and Amyotrophic Lateral Sclerosis
dc.typearticle
dspace.entity.typePublication
local.avesis.id5586d35a-165f-4971-b7e3-166cc33fc768
local.import.packageSS17
local.indexed.atWOS
local.indexed.atSCOPUS
local.indexed.atPUBMED
local.journal.numberofpages17
local.journal.quartileQ2
oaire.citation.endPage661
oaire.citation.issue11
oaire.citation.startPage645
oaire.citation.titleOMICS-A JOURNAL OF INTEGRATIVE BIOLOGY
oaire.citation.volume20
relation.isAuthorOfPublication3972a0fe-adf3-4da2-b289-7f01f80e3689
relation.isAuthorOfPublication.latestForDiscovery3972a0fe-adf3-4da2-b289-7f01f80e3689

Files

Collections

Research Outputs